Jonathan Goodman, MPhil

Antibody testing after the early stages of the SARS-CoV-2 pandemic has significantly increased in the proportion of first-time blood donors.

Caplacizumab appears to be safe and effective among patients with acquired thrombotic thrombocytopenic purpura treated in the real-world setting.